Polymorphism of the endothelial nitric oxide synthase gene is associated with diabetic retinopathy in a cohort of West Africans

Molecular Vision

Volumn 13, Issue , 2007, Pages 2142-2147

  Chen, Yuanxiu ^a   Huang, Hanxia ^a   Zhou, Jie ^a   Doumatey, Ayo ^a   Lashley, Kerrie ^a   Chen, Guanjie ^a   Agyenim Boateng, Kofi ^b   Eghan, Benjamin A ^b   Acheampong, Joseph ^b   Fasanmade, Olufemi ^c   Johnson, Thomas ^c   Akinsola, Folasade B ^c   Okafor, Godfrey ^d   Oli, Johnnie ^d   Ezepue, Felix ^d   Amoah, Albert ^e   Akafo, Stephen ^e   Adeyemo, Adebowale ^a   Rotimi, Charles N ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c UNIVERSITY OF LAGOS   (Nigeria)

^d UNIVERSITY OF NIGERIA   (Nigeria)

^e UNIVERSITY OF GHANA   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANINE; THYMINE;

ADULT; AFRICA; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE IDENTIFICATION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ALLELES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GHANA; GLYCINE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NIGERIA; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; THREONINE;

EID: 36749039854     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Palmberg PF. Diabetic retinopathy. Diabetes 1977; 26:703-9.
2. A protocol for screening for diabetic retinopathy in Europe. Retinopathy Working Party. Diabet Med 1991; 8:263-7.
3. Harris MI, Klein P, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815-9.
4. Jarrett RJ. Duration of non-insulin-dependent diabetes and development of retinopathy: analysis of possible risk factors. Diabet Med 1986; 3:261-3.
5. Patrick AW, Leslie PJ, Clarke BF, Frier BM. The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis. Diabet Med 1990; 7:902-8.
6. Sidibe EH. Diabetic retinopathy in Dakar and review of African literature: epidemiologic elements. Diabetes Metab 2000; 26:322-4.
7. Levitt NS, Bradshaw D, Zwarenstein MF, Bawa AA, Maphumolo S. Audit of public sector primary diabetes care in Cape Town, South Africa: high prevalence of complications, uncontrolled hyperglycaemia, and hypertension. Diabet Med 1997; 14:1073-7.
8. Kalk WJ, Joannou J, Ntsepo S, Mahomed I, Mahanlal P, Becker PJ. Ethnic differences in the clinical and laboratory associations with retinopathy in adult onset diabetes: studies in patients of African, European and Indian origins. J Intern Med 1997; 241:31-7.
9. Rotimi CN, Dunston GM, Berg K, Akinsete O, Amoah A, Owusu S, Acheampong J, Boateng K, Oli J, Okafor G, Onyenekwe B, Osotimehin B, Abbiyesuku F, Johnson T, Fasanmade O, Furbert-Harris P, Kittles R, Vekich M, Adegoke O, Bonney G, Collins F. In search of susceptibility genes for type 2 diabetes in West Africa: the design and results of the first phase of the AADM study. Ann Epidemiol 2001; 11:51-8.
10. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVI. The relationship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 1995; 44:796-801.
11. Liebl A. Challenges in optimal metabolic control of diabetes. Diabetes Metab Res Rev 2002 Sep-Oct; 18 Suppl 3:S36-41.
12. Rotimi C, Daniel H, Zhou J, Obisesan A, Chen G, Chen Y, Amoah A, Opoku V, Acheampong J, Agyenim-Boateng K, Eghan BA Jr, Oli J, Okafor G, Ofoegbu E, Osotimehin B, Abbiyesuku F, Johnson T, Fasanmade O, Doumatey A, Aje T, Collins F, Dunston G. Prevalence and determinants of diabetic retinopathy and cataracts in West African type 2 diabetes patients. Ethn Dis 2003; 13:S110-7.
13. Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Chevalier A, Slama G, Reach G, Selam JL. eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy. Diabet Med 2002; 19:240-5.
14. Schmidt HH, Walter U. NO at work. Cell 1994; 78:919-25.
15. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-12.
16. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-7.
17. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991; 88:4651-5.
18. Shibuki H, Katai N, Yodoi J, Uchida K, Yoshimura N. Lipid peroxidation and peroxynitrite in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2000; 41:3607-14.
19. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998; 41:1426-34.
20. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000; 77:S113-9.
21. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999; 40:689-96.
22. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100:3131-9.
23. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001; 98:2604-9.
24. Pulkkinen A, Viitanen L, Kareinen A, Lehto S, Vauhkonen I, Laakso M. Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease. J Mol Med 2000; 78:372-9.
25. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000; 49:500-3.
26. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000; 57:405-13.
27. Buraczynska M, Ksiazek P, Zaluska W, Nowicka T, Ksiazek A. Endothelial nitric oxide synthase gene intron 4 polymorphism in patients with end-stage renal disease. Nephrol Dial Transplant 2004; 19:2302-6.
28. Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, Takada K, Oteki T, Obara M, Aoyagi K, Koyama A. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem 2003; 244:113-8.
29. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004; 109:1359-65.
30. Rao S, Austin H, Davidoff MN, Zafari AM. Endothelial nitric oxide synthase intron 4 polymorphism is a marker for coronary artery disease in African-American and Caucasian men. Ethn Dis 2005; 15:191-7.
31. Awata T, Neda T, Iizuka H, Kurihara S, Ohkubo T, Takata N, Osaki M, Watanabe M, Nakashima Y, Sawa T, Inukai K, Inoue I, Shibuya M, Mori K, Yoneya S, Katayama S. Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes. Diabetes Care 2004; 27:2184-90.
32. Frost D, Chitu J, Meyer M, Beischer W, Pfohl M. Endothelial nitric oxide synthase (ecNOS) 4 a/b gene polymorphism and carotid artery intima-media thickness in type-1 diabetic patients. Exp Clin Endocrinol Diabetes 2003; 111:12-5.
33. Gardemann A, Lohre J, Cayci S, Katz N, Tillmanns H, Haberbosch W. The T allele of the missense Glu(298)Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. Atherosclerosis 2002; 160:167-75.
34. Shoji M, Tsutaya S, Saito R, Takaman H, Yasujima M. Positive association of endothelial nitric oxide synthase gene polymorphism with hypertension in northern Japan. Life Sci 2000; 66:2557-62.
35. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, Biagini A, Clerico A. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003; 49:389-95.
36. Kishimoto T, Misawa Y, Kaetu A, Nagai M, Osaki Y, Okamoto M, Yoshida S, Kurosawa Y, Fukumoto S. eNOS Glu298Asp polymorphism and hypertension in a cohort study in Japanese. Prev Med 2004; 39:927-31.
37. Guzik TJ, Black E, West NE, McDonald D, Ratnatunga C, Pillai R, Channon KM. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 2001; 100:130-7.
38. Schmoelzer I, Renner W, Paulweber B, Malaimare L, Iglseder B, Schmid P, Schallmoser K, Wascher TC. Lack of association of the Glu298Asp polymorphism of endothelial nitric oxide synthase with manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian populations. Eur J Clin Invest 2003; 33:191-8.
39. Luke AH, Rotimi CN, Cooper RS, Long AE, Forrester TE, Wilks R, Bennett FI, Ogunbiyi O, Compton JA, Bowsher RR. Leptin and body composition of Nigerians, Jamaicans, and US blacks. Am J Clin Nutr 1998; 67:391-6.
40. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am 2004; 88:1001-36,xi.
41. Du Y, Smith MA, Miller CM, Kern TS. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002; 80:771-9.
42. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. L-arginine transport in retinas from streptozotocin diabetic rats: correlation with the level of IL-1 beta and NO synthase activity. Vision Res 1999; 39:3817-23.
43. Ozden S, Tatlipinar S, Bicer N, Yaylali V, Yildirim C, Ozbay D, Guner G. Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy. Can J Ophthalmol 2003; 38:393-6.
44. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, Savli H. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 2002; 16:163-70.
45. Yilmaz G, Esser P, Kociok N, Aydin P, Heimann K, Kociek N. Elevated vitreous nitric oxide levels in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2000; 130:87-90. Erratum in: Am J Ophthalmol 2001 Jan; 131(1):159.
46. Tsai DC, Chiou SH, Lee FL, Chou CK, Chen SJ, Peng CH, Kuo YH, Chen CF, Ho LL, Hsu WM. Possible involvement of nitric oxide in the progression of diabetic retinopathy. Ophthalmologica 2003 Sep-Oct; 217:342-6.
47. Hattenbach LO, Allers A, Klais C, Koch F, Hecker M. L-Arginine-nitric oxide pathway-related metabolites in the aqueous humor of diabetic patients. Invest Ophthalmol Vis Sci 2000; 41:213-7.
48. Cheon EW, Park CH, Kang SS, Cho GJ, Yoo JM, Song JK, Choi WS. Change in endothelial nitric oxide synthase in the rat retina following transient ischemia. Neuroreport 2003; 14:329-33.
49. Haverkamp S, Kolb H, Cuenca N. Endothelial nitric oxide synthase (eNOS) is localized to Muller cells in all vertebrate retinas. Vision Res 1999; 39:2299-303.
50. Warpeha KM, Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003; 17:305-11.
51. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003; 44:3135-43.
52. Salgo MG, Squadrito GL, Pryor WA. Peroxynitrite causes apoptosis in rat thymocytes. Biochem Biophys Res Commun 1995; 215:1111-8.
53. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162:1995-2004.
54. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 1993; 90:7240-4.
55. Wang J, Dudley D, Wang XL. Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 2002; 22:e1-4.